Thwarting AAV-Neutralizing Antibodies Could Improve Gene Therapy
Thwarting AAV-Neutralizing Antibodies Could Improve Gene Therapy
Adeno-associated viral vectors can deliver gene therapies, but AAV-neutralizing antibodies might prevent the medicines from working.
Thwarting AAV-Neutralizing Antibodies Could Improve Gene Therapy
Thwarting AAV-Neutralizing Antibodies Could Improve Gene Therapy

Adeno-associated viral vectors can deliver gene therapies, but AAV-neutralizing antibodies might prevent the medicines from working.

Adeno-associated viral vectors can deliver gene therapies, but AAV-neutralizing antibodies might prevent the medicines from working.

immunity
Vector-Based Vaccines Come to the Fore in the COVID-19 Pandemic
Vector-Based Vaccines Come to the Fore in the COVID-19 Pandemic
Anthony King | Sep 8, 2020
Adenovirus vectors deliver the genetic instructions for SARS-CoV-2 antigens directly into patients’ cells, provoking a robust immune response. But will pre-existing immunity from common colds take them down?
COVID-19 Antibodies Last for at Least Four Months After Recovery
COVID-19 Antibodies Last for at Least Four Months After Recovery
Amanda Heidt | Sep 2, 2020
The results from a study in Iceland can’t say if a recovered patient’s antibodies can protect them from subsequent reinfection.
Patients Reinfected with Coronavirus in Hong Kong, Europe
Patients Reinfected with Coronavirus in Hong Kong, Europe
Lisa Winter | Aug 25, 2020
So far, there are three patients known to have been infected with SARS-CoV-2 twice, and in at least one case the second time around was asymptomatic.
Some COVID-19 Patients Lack Key Structures for Antibody Creation
Some COVID-19 Patients Lack Key Structures for Antibody Creation
Katarina Zimmer | Aug 25, 2020
An absence of germinal centers—which arise during infections to produce long-lived antibody-generating cells—might explain rapidly waning antibody levels in the disease.
Differences in Antibody Responses Linked to COVID-19 Outcomes
Differences in Antibody Responses Linked to COVID-19 Outcomes
Katarina Zimmer | Aug 18, 2020
In a small study of patients hospitalized due to SARS-CoV-2 infection, researchers report distinct early differences between the antibody responses of patients who recovered and those who died, possibly paving the way for a tool to predict disease prognosis.
Cold-Causing Coronaviruses Don’t Seem to Confer Lasting Immunity
Cold-Causing Coronaviruses Don’t Seem to Confer Lasting Immunity
Shawna Williams | Aug 18, 2020
Studies on SARS-CoV-2’s milder cousins hint that our immune systems are quick to forget the viruses, but it’s unclear whether the same is true for the agent that causes COVID-19.
Does the Common Cold Protect You from COVID-19?
Does the Common Cold Protect You from COVID-19?
Chris Baraniuk | Aug 4, 2020
There are emerging signs that some people might have heightened protection against SARS-CoV-2, perhaps thanks to recent infection by other coronaviruses.
Studies Report Rapid Loss of COVID-19 Antibodies
Studies Report Rapid Loss of COVID-19 Antibodies
Amanda Heidt | Jun 19, 2020
The results, while preliminary, suggest that survivors of SARS-CoV-2 infection may be susceptible to reinfection within weeks or months.
Neutrophil Extracellular Traps May Augur Severe COVID-19
Neutrophil Extracellular Traps May Augur Severe COVID-19
Alakananda Dasgupta | May 28, 2020
These webs of chromatin and proteins, released by immune cells to control microbial infections, could serve as a therapeutic target in coronavirus infections.